INVO Fertility, Inc.

INVO Fertility, Inc. is a healthcare services company specializing in assisted reproductive technologies within the fertility marketplace. The company is notable for its development and distribution of the INVOcell device, a proprietary medical device that enables fertilization and early embryo development to occur in vivo inside a woman's body. INVO Fertility operates fertility clinics, including the INVO Centers, and offers clinic services aimed at expanding access to advanced fertility treatments. Additionally, the company engages in biopharmaceutical research, developing therapeutic candidates such as NY-303, a bifunctional antibody in clinical trials for hepatocellular carcinoma, highlighting its diversified focus on fertility and related therapeutic areas. Founded in 2007 and based in Sarasota, Florida, INVO Fertility positions itself as a healthcare innovator in reproductive technology and fertility clinic services, contributing to expanded, patient-centered fertility care.